** Shares of biotech firm Cullinan Therapeutics CGEM.O rise 5.39% to $13.89

** Co says CLN-978 showed remission in a rheumatoid arthritis patient within four weeks and reduced disease-causing antibodies

** CGEM's velinotamig, an experimental drug, led to complete kidney response in two lupus nephritis patients, a condition that damages the kidneys, co says

** Co says drugs target autoimmune diseases where the immune system attacks the body, leading to joint pain in rheumatoid arthritis and organ damage in lupus

** No serious side effects reported across both early-stage studies, co says

** Co plans to expand trials into more diseases including blood disorders and share more data later this year, co says

** Including session's move, stock up ~34% YTD